Kanamori Masayuki, Kikuchi Atsuo, Watanabe Mika, Shibahara Ichiyo, Saito Ryuta, Yamashita Yoji, Sonoda Yukihiko, Kumabe Toshihiro, Kure Shigeo, Tominaga Teiji
Departments of Neurosurgery and.
J Neurosurg. 2014 Jun;120(6):1288-97. doi: 10.3171/2014.3.JNS131505. Epub 2014 Apr 18.
Intraoperative diagnosis is important in determining the strategies during surgery for glioma. Because the mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes have diagnostic, prognostic, and predictive values, the authors assessed the feasibility and significance of a simplified method for the intraoperative detection of IDH1 and IDH2 gene mutations.
Rapid DNA extraction, amplification with conventional polymerase chain reaction (PCR) or co-amplification at lower denaturation temperature PCR (COLD-PCR), and fluorescence melting curve analysis with adjacent hybridization probes were performed for the intraoperative detection of IDH1 and IDH2 mutations in 18 cases of suspected nonneoplastic lesions and low- and high-grade gliomas and in 3 cases of radiation necrosis.
DNA extraction for detection of the mutation took 60-65 minutes. The results of this assay showed complete correlation with that of Sanger sequencing. The sensitivity for detection of mutations in a background of wild-type genes was 12.5% and 2.5% in conventional PCR and COLD-PCR, respectively. The diagnosis of glioma was established in 3 of 5 cases in which definitive diagnosis was not obtained using frozen sections, and information was obtained for the discrimination of glioblastoma or glioblastoma with an oligodendroglioma component from anaplastic glioma or secondary glioblastoma. This assay also detected a small fraction of tumor cells with IDH1 mutation in radiation necrosis.
These methods provide important information for establishing the differential diagnosis between low-grade glioma and nonneoplastic lesions and the diagnosis for subtypes of high-grade glioma. Although tumor cells in radiation necrosis were detected with a high sensitivity, further investigation is necessary for clinical application in surgery for recurrent glioma.
术中诊断对于确定胶质瘤手术策略至关重要。由于异柠檬酸脱氢酶1和2(IDH1和IDH2)基因的突变具有诊断、预后和预测价值,作者评估了一种简化的术中检测IDH1和IDH2基因突变方法的可行性和意义。
对18例疑似非肿瘤性病变、低级别和高级别胶质瘤以及3例放射性坏死病例进行快速DNA提取、常规聚合酶链反应(PCR)扩增或低温变性温度PCR(COLD-PCR)共扩增,并使用相邻杂交探针进行荧光熔解曲线分析,以术中检测IDH1和IDH2突变。
用于检测突变的DNA提取耗时60 - 65分钟。该检测结果与桑格测序结果完全相关。在野生型基因背景下,常规PCR和COLD-PCR检测突变的灵敏度分别为12.5%和2.5%。在5例使用冰冻切片未获得明确诊断的病例中,有3例确诊为胶质瘤,并且获得了用于鉴别胶质母细胞瘤或伴有少突胶质细胞瘤成分的胶质母细胞瘤与间变性胶质瘤或继发性胶质母细胞瘤的信息。该检测还在放射性坏死中检测到一小部分具有IDH1突变的肿瘤细胞。
这些方法为建立低级别胶质瘤与非肿瘤性病变的鉴别诊断以及高级别胶质瘤亚型的诊断提供了重要信息。尽管在放射性坏死中检测肿瘤细胞的灵敏度较高,但在复发性胶质瘤手术的临床应用中仍需进一步研究。